SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rosetta Inpharmatics (RSTA) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (15)11/30/2000 3:11:15 PM
From: Dan Spillane  Read Replies (1) | Respond to of 31
 
My understanding is the Rosetta software is unique in approach and can analyze effects both more quickly and more comprehensively. I have some limited understanding of genetics and genomics...besides being faster, is it correct to say they can examine multiple ("pleotropic"?) effects of a gene or genes more readily than others?

I don't think Wall Street has caught on about this yet. Apparently, Monsanto and Abbott have-both leaders in specific areas.

I haven't seen major coverage of this stock yet. Seems like a sleeper.



To: nigel bates who wrote (15)12/11/2000 1:08:11 PM
From: tuck  Read Replies (2) | Respond to of 31
 
nigel,

This is strange, indeed. A solid day in the markets, including biotech. RSTA announces another good win and the selling continues, with lock-up expiration almost two months away (and not the worst overhang I've seen, either). Anyone got a clue as to why?

siliconinvestor.com

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News